Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma

Human Pathology

Volumn 23, Issue 2, 1992, Pages 107-116

  Sheibani, Khalil ^a   Esteban, Jose M ^a   Bailey, Anne ^a   Battifora, Hector ^a   Weiss, Lawrence M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

diagnostic aids; DNA; immunophenotype; malignant mesothelioma; molecular biology; ploidy

Indexed keywords

CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; LECTIN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; VIMENTIN;

CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; GENE EXPRESSION; IMMUNOPATHOLOGY; LUNG ADENOCARCINOMA; MALIGNANT MESOTHELIOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW;

DNA, NEOPLASM; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MESOTHELIOMA; PLOIDIES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026581795     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/0046-8177(92)90231-Q     Document Type: Article

References (57)

1. Pleura
2. Malignant mesotheliomas: Ultrastructural distinction from adenocarcinoma
3. A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells
4. Leu-M1 and agglutin stain the neoplastic cells of Hodgkin's disease
5. Leu-M1 positivity not specific for Hodgkin's disease
6. Leu-M1 in human neoplasms: An immunohistologic study of 400 cases
7. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: An immunohistologic analysis demonstrating the value of Leu M1 antigen
8. Further evidence demonstrating the value of Leu-M1 antigen in differential diagnosis of malignant mesothelioma and adenocarcinoma: An immunohistologic evaluation of 395 cases
9. Immunohistochemical staining of malignant mesotheliomas
10. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma: A bi-institutional study of 47 cases
11. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: The role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule derived antigen
12. Expression of “myelomonocytic” antigens in mesotheliomas and adenocarcinomas involving serosal surfaces
13. Malignant epithelial pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases
14. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12
15. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody B72.3
16. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen
17. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells
18. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach
19. Use of antibodies to carcinoembryonic antigen and human fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium
20. Immunocytology in malignant pleural mesothelioma: Expression of tumor markers and distribution of lymphocyte subsets
21. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma
22. Mesothelioma: Profile of keratin proteins and carcinoembryonic antigen
23. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma
24. Unusual granular reactivity for carcinoembryonic antigen in malignant mesothelioma
25. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms
26. Diagnostic uses of antibodies to keratins A review and immunohistochemical comparison of seven monoclonal and three polyclonal antibodies
27. Three types of spindle cell tumors of the pleura: Fibroma, sarcoma, and sarcomatoid mesothelioma
28. Localized fibrous tumor of the serosal cavities: Immunohistochemical, electron-microscopic, and flow-cytometric DNA study
29. Localized benign and malignant fibrous tumors of the pleura: A clinicopathologic review of 223 cases
30. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions: Comparison with intermediate filament distribution by electron microscopy
31. Distinct keratin patterns demonstrated by immunoperoxidase staining of adenocarcinomas, carcinoids, and mesotheliomas using polyclonal and monoclonal antikeratin antibodies
32. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma
33. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma
34. The distribution of vimentin and keratin in epithelial and non-epithelial neoplasms: A comprehensive immunohistochemical study on formalin-and alcohol-fixed tissues
35. Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia
36. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinomas
37. Monoclonal antibody 44-3A6 as a probe for a novel antigen found on human lung carcinomas with glandular differentiation
38. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and plural malignant mesothelioma
39. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung
40. Monoclonal antibodies to human malignant mesothelioma
41. Establishment of human mesothelioma cell lines (MS-1,-2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential
42. Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody
43. Monoclonal antibodies against mesothelial membrane antigen discriminate between mesothelioma and lung adenocarcinoma
44. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies
45. Flow cytometric analysis of malignant pleural mesotheliomas
46. Epithelioid pleural mesotheliomas and pulmonary adenocarcinomas: A comparative DNA flow cytometric (FCM) study
47. Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma
48. DNA analysis by flow cytometry in malignant pleural mesothelioma: Relationship to histology and survival
49. Effects of various fixatives and fixation conditions on DNA ploidy analysis: A need for strict internal DNA standards
50. Cytogenetic analysis of malignant mesothelioma
51. Chromosome changes in malignant mesothelioma
52. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma
53. Growth factor production by normal human mesothelial cells and mesothelioma cell lines
54. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors
55. Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms
56. Reported binding of monoclonal antibody RAP-5 to formalin-fixed tissue sections is not indicative of ras P21 expression
57. Analysis of Ha-ras sequence in DNAs of malignant mesothelioma and pulmonary adenocarcinoma by a sensitive polymerase chain reaction (PCR) method